Cellular DEL Screening Market Size, Trends & Growth Opportunity By Screening Technology, By Chemistry Platform, By Therapeutic Application, By End User, By Region and Forecast Till 2030

Report ID : AMR1006188 | Industries : Healthcare | Published On :September 2026 | Page Count : 215

Request Sample
Ask for Customization

Cellular DNA-encoded library (DEL) screening is a drug discovery technology market covering the platforms, chemistry libraries and screening services pharmaceutical and biotech organizations use to identify small-molecule hits against a target of interest without first synthesizing and testing each candidate individually.

A DNA-encoded library attaches a unique DNA barcode to each small molecule in a very large synthesized chemical collection, so that after a screening round the surviving molecules can be identified by sequencing their DNA tags rather than by testing each compound one at a time.

This report defines the market around six screening technology categories, cellular DEL screening, live cell-based DEL screening, phenotypic DEL screening, target-based DEL screening, affinity selection DEL screening and covalent DEL screening, together with five DEL chemistry platform categories that determine what kind of library a given screening technology can be run against.

The market spans the full discovery workflow from target identification through candidate selection, and is used across therapeutic areas including oncology, immunology and inflammation, neuroscience, infectious diseases, metabolic disorders, rare diseases and cardiovascular diseases.

End users range from large pharmaceutical companies and emerging biotech firms to contract research organizations, academic research institutes, translational medicine centers and government research organizations, each accessing DEL screening through a different engagement model.

This page describes screening technology, chemistry platform, discovery stage, target class, therapeutic application, end user, engagement model and regulatory environment strictly as market categories, and states no claim about hit rate, hit validation success rate or comparative screening performance for any technology, platform or company.

Market Size and Growth Forecast (2026 to 2030)

The global cellular DEL screening market is estimated at approximately USD 1.6 Billion in 2025 and is forecast to reach approximately USD 2.9 Billion by 2030, growing at a compound annual growth rate of approximately 12.6 percent across the forecast period.

This estimate is derived by triangulating a published total DNA-encoded library market baseline against this report's own screening-technology and chemistry-platform segmentation boundary, with the full derivation set out in the Research Methodology section below.

MetricValue
Market Size (2025)Approximately USD 1.6 Billion
Forecast Size (2030)Approximately USD 2.9 Billion
CAGR (2025-2030)Approximately 12.6%
Base Year2025
Forecast Period2026-2030 (5-year)
Scope NoteCellular, live cell-based, phenotypic, target-based, affinity selection and covalent DNA-encoded library (DEL) screening technologies, chemistry platforms and related discovery partnership services; excludes conventional biochemical high-throughput screening not based on DNA-encoded library chemistry and excludes the pharmaceutical treatments that any resulting drug candidate might eventually become
Largest Screening Technology CategoryAffinity Selection DEL Screening
Fastest-Growing Screening Technology CategoryCellular DEL Screening
Largest Therapeutic Application CategoryOncology
Fastest-Growing Therapeutic Application CategoryImmunology & Inflammation
Largest Regional ConcentrationNorth America
Fastest-Growing RegionAsia-Pacific

 

Market Drivers

Rising novel target discovery requirements among pharmaceutical and biotech drug discovery teams are a primary driver, as organizations pursue difficult-to-drug targets such as GPCRs, protein-protein interactions and E3 ligases that conventional biochemical screening approaches have historically struggled to address.

Internal pipeline expansion and portfolio diversification among global pharmaceutical companies continue to expand discovery partnership demand, as R&D leadership and therapeutic area heads look to DEL screening to accelerate hit identification across a broader set of target classes than their existing in-house capabilities can cover alone.

Growing integration of AI and computational chemistry with DNA-encoded library screening is expanding hit triage and library design capabilities, letting discovery partnership programs process larger encoded libraries and prioritize candidate hits faster than manual triage alone could support.

Expansion of discovery partnership programs, co-development agreements and platform access models between pharmaceutical companies, biotech firms and specialized DEL screening providers is broadening how buyers can access this technology, moving beyond single-project fee-for-service engagements toward multi-year strategic platform relationships.

MARKET SHIFT

Discovery partnership programs and platform access models are gaining ground relative to single-project fee-for-service screening, as pharmaceutical companies increasingly favor multi-year strategic relationships that give their discovery teams repeated access to a provider's library and chemistry platform rather than a one-time screening engagement.

 

Market Restraints

Long scientific assessment and pilot validation cycles before a pharmaceutical or biotech partner commits to a multi-year discovery partnership or platform access agreement can slow how quickly a new screening provider or chemistry platform gains adoption, since discovery program leaders typically require a demonstrated pilot round before expanding to a full program-based agreement.

Dependence on pharmaceutical and biotech R&D budget cycles governs discovery partnership commitments and sits outside any screening provider's control, meaning a broader pullback in R&D spending among top-tier pharma accounts can directly slow new contract signings regardless of a provider's own technology strengths.

Competition between proprietary DEL platform developers, fee-for-service providers and large pharmaceutical companies' own in-house DEL technology platforms fragments partnership demand, since a growing share of Top 20 Global Pharma accounts have built internal DEL capabilities that compete for the same discovery budget as external providers.

Regulatory developments affecting discovery programs, including the distinction between GLP-compliant and non-GLP research programs, shape which screening programs a buyer can specify, adding a qualification step that can lengthen the sales cycle for providers whose programs are not already aligned to a buyer's required regulatory and quality environment.

PROCUREMENT INSIGHT

Buyers increasingly request a screening provider's regulatory and quality environment alignment, GLP-compliant, non-GLP, preclinical or translational research program, before committing to a pilot validation round, since mismatched program designation is one of the more common reasons a promising pilot fails to convert into a full discovery partnership.

 

Market Opportunities

Considerable untapped opportunity exists across underserved target classes and emerging therapeutic opportunities identified in this report's competitive mapping, particularly where difficult-to-drug target categories such as transcription factors and novel intracellular targets remain thinly served relative to more established target classes.

Geographic coverage gaps and service differentiation opportunities exist relative to the concentration of established DEL platform capacity among current providers, since discovery partnership activity remains heavily weighted toward a small number of biotech corridors even as buyer demand broadens across additional countries.

AI-enabled discovery integration gaps present a further opportunity, as several providers are still building out computational chemistry and machine-learning-assisted library design capabilities that more advanced competitors have already integrated into their screening technology offering.

Growth in translational medicine programs and expansion among top-tier pharma accounts is extending discovery partnership demand beyond established target classes, creating room for providers with broader chemistry platform portfolios to capture business that a narrower single-platform specialist cannot address.

Cellular DEL Screening Technologies and Chemistry Platforms

Screening technology choice is the first specification decision in any DEL screening program, since whether a discovery team uses cellular, live cell-based, phenotypic, target-based, affinity selection or covalent DEL screening determines which chemistry platforms and library designs are even viable before therapeutic application or target class is considered.

A full breakdown of these six screening technology categories, alongside the five DEL chemistry platform categories, DNA-encoded small molecule libraries, macrocyclic DEL platforms, peptide-based DEL platforms, DNA-templated chemistry platforms and proprietary encoded chemistry platforms, is covered in this report's cellular DEL screening technology and chemistry platform breakdown, which treats screening technology and chemistry platform choice as one connected specification decision rather than two unrelated segmentation lists.

Providers with breadth across multiple screening technologies and chemistry platforms are generally better positioned to serve a discovery partner whose target class or therapeutic focus shifts partway through a multi-year engagement, since the underlying library and screening approach can be adjusted without changing providers.

DEL Screening Discovery Stages and Target Classes

DEL screening demand originates across five discovery stage categories, target identification, hit discovery, hit validation, lead optimization and candidate selection, and seven target class categories spanning GPCRs, kinases, protein-protein interactions, transcription factors, ion channels, E3 ligases and novel intracellular targets.

Target class breadth, not any single target class alone, defines this screening category, and this report's discovery stage and target class segmentation explains why difficult-to-drug target categories such as E3 ligases and novel intracellular targets are a central reason buyers turn to DEL screening rather than conventional biochemical screening in the first place.

Discovery stage and target class together shape which engagement model a buyer is likely to select, since an early-stage target identification program against a novel target class typically carries different risk and commitment characteristics than a later-stage lead optimization program against an already-validated target.

DEL Screening Therapeutic Applications and End Users

Therapeutic application breadth across oncology, immunology and inflammation, neuroscience, infectious diseases, metabolic disorders, rare diseases and cardiovascular diseases is matched by end user diversity spanning large pharmaceutical companies, emerging biotech companies, contract research organizations, academic research institutes, translational medicine centers and government research organizations.

This report's therapeutic application and end user segmentation shows that end user diversity, not large pharmaceutical companies alone, defines this screening market's buyer base, since emerging biotech firms, CROs and academic consortia together represent a substantial and growing share of discovery partnership activity.

Oncology remains the largest therapeutic application category by discovery partnership volume, while immunology and inflammation programs are expanding at a faster relative pace as difficult-to-drug immune-pathway targets draw increased discovery partnership investment.

DEL Screening Engagement Models and Purchasing Pathways

Buyers access cellular DEL screening through five engagement model categories, fee-for-service screening, discovery partnership programs, co-development agreements, licensing arrangements and platform access models, each operating under one of four regulatory and quality environment categories, GLP-compliant discovery programs, non-GLP research programs, preclinical development programs and translational research programs.

Engagement model choice is a structural decision tied to a program's regulatory and quality environment, not just a contract term, and this report's engagement model and purchasing pathway breakdown explains how that pairing shapes which procurement route a given discovery program can realistically follow.

Discovery program leaders and business development groups typically select an engagement model based on how much internal control over library design and screening cadence a program requires, with platform access models suiting buyers who want ongoing internal access and fee-for-service screening suiting buyers with a narrower, defined screening need.

Cellular DEL Screening Market, By Region

North America holds the largest regional concentration in the cellular DEL screening market, anchored by the US East Coast biotech corridor and US West Coast innovation hub, alongside a substantial Canadian research base, reflecting the concentration of top-tier pharma accounts and venture-backed biotech firms headquartered across the United States and Canada.

Europe represents a well-established regional base for this market, with Denmark, the United Kingdom, Germany, France, Switzerland, the Netherlands, Sweden and Belgium each hosting active DEL screening demand clusters, including the UK Golden Triangle, the Swiss Life Sciences Cluster and the Nordic Drug Discovery Ecosystem centered on Copenhagen.

Asia-Pacific is the fastest-growing region tracked in this report, with China, Japan, South Korea, Singapore and Australia each contributing to demand growth as China's biopharma innovation centers expand their own drug discovery investment and increasingly engage international DEL screening partners alongside domestic capability building.

State and city level demand clusters named in this report cut across all three regions covered, including Copenhagen, Cambridge, Oxford, London, Basel, Zurich, Berlin, Munich and Paris in Europe, Boston, San Diego, the San Francisco Bay Area, New York and Toronto in North America, and Shanghai, Beijing, Tokyo, Osaka, Seoul and Singapore in Asia-Pacific.

REGIONAL OPPORTUNITY

Asia-Pacific's growth is not limited to China. South Korea, Japan and Singapore are each expanding their own drug discovery investment, and DEL screening providers with an established Asia-Pacific presence are increasingly well placed to capture discovery partnership demand from biotech firms across all three countries rather than China alone.

 

Leading Companies

The competitive landscape for cellular DEL screening spans specialist DEL platform providers, in-house pharmaceutical DEL platforms operated by large pharma accounts, and contract research organizations offering DEL screening among their broader discovery service portfolios.

Companies covered in this report include Vipergen, X-Chem, HitGen, WuXi AppTec, Deluge Biotechnologies, Nuevolution, GSK DEL Technologies, Pfizer Center for DNA-Encoded Chemistry, Novartis DEL Platform, AstraZeneca Discovery Sciences, Bristol Myers Squibb Discovery Platforms, Roche Pharma Research & Early Development, AbbVie Discovery Research, Genentech, Exscientia Discovery Partnerships, Proteros biostructures, Evotec and Charles River Laboratories.

How each provider type relates to different buyer needs is set out in this report's supplier landscape by provider type, which separates specialist platform providers from in-house pharma platforms and CRO or discovery-service providers competing alongside them.

Strategic developments tracked across this competitive landscape include drug discovery collaborations, pharmaceutical partnerships, platform expansions, technology licensing agreements, investment and funding activity, and research alliances between specialist providers and academic or pharma partners.

Beyond This Page

The full Cellular DEL Screening Market report extends well beyond what this page can cover, with detailed company profiles, discovery partnership economics, competitive benchmarking and country-level demand data available to report purchasers.

Buyers evaluating a DEL screening partnership, and providers benchmarking their own market position, can use this page's five linked segmentation views as a starting point before accessing the complete underlying data set in the full report.

Frequently Asked Questions

The global cellular DEL screening market is estimated at approximately USD 1.6 Billion in 2025 and is forecast to reach approximately USD 2.9 Billion by 2030, growing at a compound annual growth rate of approximately 12.6 percent, derived by triangulating a published total DNA-encoded library market estimate against this report's own segmentation boundary.

This report covers six screening technology categories: cellular DEL screening, live cell-based DEL screening, phenotypic DEL screening, target-based DEL screening, affinity selection DEL screening and covalent DEL screening, alongside five DEL chemistry platform categories that determine which library types each technology can be run against.

North America holds the largest regional concentration, anchored by the US East Coast and West Coast biotech corridors, while Asia-Pacific is the fastest-growing region, led by China's expanding biopharma innovation centers alongside growth in Japan, South Korea, Singapore and Australia.

Oncology is the largest therapeutic application category by discovery partnership volume, with immunology and inflammation programs growing at a faster relative pace as difficult-to-drug immune-pathway targets draw increased investment; neuroscience, infectious diseases, metabolic disorders, rare diseases and cardiovascular diseases round out this report's seven tracked therapeutic application categories.

End users include large pharmaceutical companies, emerging biotech companies, contract research organizations, academic research institutes, translational medicine centers and government research organizations, each typically accessing DEL screening through a different engagement model suited to its own discovery budget and program structure.

Buyers can access DEL screening through fee-for-service screening, discovery partnership programs, co-development agreements, licensing arrangements or platform access models, with the choice generally shaped by how much internal control over library design and screening cadence a program requires.

Companies covered include Vipergen, X-Chem, HitGen, WuXi AppTec, Deluge Biotechnologies, Nuevolution, GSK DEL Technologies, Pfizer Center for DNA-Encoded Chemistry, Novartis DEL Platform, AstraZeneca Discovery Sciences, Bristol Myers Squibb Discovery Platforms, Roche Pharma Research & Early Development, AbbVie Discovery Research, Genentech, Exscientia Discovery Partnerships, Proteros biostructures, Evotec and Charles River Laboratories.

This report tracks seven target class categories: GPCRs, kinases, protein-protein interactions, transcription factors, ion channels, E3 ligases and novel intracellular targets, several of which are difficult-to-drug categories that conventional biochemical screening approaches have historically struggled to address.

No. Conventional high-throughput biochemical screening tests compounds individually against a target, while DEL screening attaches a unique DNA barcode to each molecule in a very large synthesized library so that surviving hits can be identified by sequencing rather than one-by-one testing, which is why this report treats DEL screening as a distinct technology category.

Inquire Before Buying Request Free Sample Ask For Discount

1. Introduction

1.1. Objective of the Study

1.2. Market Definition

1.3. Market Scope

2. Executive Summary

3. Cellular DEL Screening Market Analysis and Forecast (2026–2030)

3.1. Overview

3.2. Market Dynamics

3.3. Drivers

3.3.1. Rising Novel Target Discovery Requirements Among Pharmaceutical and Biotech Drug Discovery Teams Pursuing Difficult-to-Drug Targets Such as GPCRs, Protein-Protein Interactions and E3 Ligases.

3.3.2. Internal Pipeline Expansion and Portfolio Diversification Among Global Pharmaceutical Companies, Driving Accelerated Hit Identification Through DNA-Encoded Library Screening Partnerships.

3.3.3. Growing Integration of AI and Computational Chemistry with DNA-Encoded Library Screening, Expanding Hit Triage and Library Design Capabilities Across Discovery Partnerships.

3.3.4. Expansion of Discovery Partnership Programs and Co-Development Agreements Between Pharmaceutical Companies, Biotech Firms and Specialized DEL Screening Providers.

3.4. Restraints

3.4.1. Long Scientific Assessment and Pilot Validation Cycles Before a Pharmaceutical or Biotech Partner Commits to a Multi-Year Discovery Partnership or Platform Access Agreement.

3.4.2. Dependence on Pharmaceutical and Biotech R&D Budget Cycles, Which Govern Discovery Partnership Commitments and Sit Outside Any Screening Provider's Control.

3.4.3. Competition Between Proprietary DEL Platform Developers, Fee-for-Service Providers and Large Pharmaceutical Companies' Own In-House DEL Technology Platforms, Which Fragments Partnership Demand.

3.4.4. Regulatory Developments Affecting Discovery Programs, Including the Distinction Between GLP-Compliant and Non-GLP Research Programs, Which Shape Which Screening Programs a Buyer Can Specify.

3.5. Opportunities

3.5.1. Considerable Untapped Opportunity Identified in the Report's Competitive Mapping Across Underserved Target Classes and Emerging Therapeutic Opportunities.

3.5.2. Geographic Coverage Gaps and Service Differentiation Opportunities Identified in the Report's Competitive Mapping, Relative to the Concentration of Established DEL Platform Capacity Among Current Providers.

3.5.3. AI-Enabled Discovery Integration Gaps, Which Several Providers Are Addressing to Differentiate Their Screening Technology and Library Design Capabilities.

3.5.4. Growth in Translational Medicine Programs and Expansion Among Top-Tier Pharma Accounts, Extending Discovery Partnership Demand Beyond Established Target Classes.

3.6. Porter's Five Forces Model

3.7. Value Chain Analysis

4. Screening Technology

4.1. Cellular DEL Screening

4.2. Live Cell-Based DEL Screening

4.3. Phenotypic DEL Screening

4.4. Target-Based DEL Screening

4.5. Affinity Selection DEL Screening

4.6. Covalent DEL Screening

5. DEL Chemistry Platform

5.1. DNA-Encoded Small Molecule Libraries

5.2. Macrocyclic DEL Platforms

5.3. Peptide-Based DEL Platforms

5.4. DNA-Templated Chemistry Platforms

5.5. Proprietary Encoded Chemistry Platforms

6. Discovery Stage

6.1. Target Identification

6.2. Hit Discovery

6.3. Hit Validation

6.4. Lead Optimization

6.5. Candidate Selection

7. Therapeutic Application

7.1. Oncology

7.2. Immunology & Inflammation

7.3. Neuroscience

7.4. Infectious Diseases

7.5. Metabolic Disorders

7.6. Rare Diseases

7.7. Cardiovascular Diseases

8. Target Class

8.1. GPCRs

8.2. Kinases

8.3. Protein-Protein Interactions

8.4. Transcription Factors

8.5. Ion Channels

8.6. E3 Ligases

8.7. Novel Intracellular Targets

9. End User

9.1. Large Pharmaceutical Companies

9.2. Emerging Biotech Companies

9.3. Contract Research Organizations (CROs)

9.4. Academic Research Institutes

9.5. Translational Medicine Centers

9.6. Government Research Organizations

10. Engagement Model

10.1. Fee-for-Service Screening

10.2. Discovery Partnership Programs

10.3. Co-Development Agreements

10.4. Licensing Arrangements

10.5. Platform Access Models

11. Regulatory & Quality Environment

11.1. GLP-Compliant Discovery Programs

11.2. Non-GLP Research Programs

11.3. Preclinical Development Programs

11.4. Translational Research Programs

12. Buyer Intelligence and Demand Landscape

12.1. Buyer Segmentation

12.1.1. Global Pharmaceutical Companies

12.1.2. Mid-Sized Drug Developers

12.1.3. Venture-Backed Biotech Firms

12.1.4. Specialty Discovery Companies

12.1.5. Academic Consortia

12.2. Buyer Industries

12.2.1. Pharmaceuticals

12.2.2. Biotechnology

12.2.3. Precision Medicine

12.2.4. Cell Therapy Research

12.2.5. Genomics & Proteomics

12.3. Buyer Company Types

12.3.1. Innovator Drug Developers

12.3.2. Platform Biotechnology Firms

12.3.3. Discovery Service Providers

12.3.4. Academic Research Networks

12.4. Country-Wise Buyer Mapping

12.4.1. United States

12.4.2. United Kingdom

12.4.3. Germany

12.4.4. Switzerland

12.4.5. France

12.4.6. Denmark

12.4.7. China

12.4.8. Japan

12.4.9. South Korea

12.5. Regional Demand Clusters

12.5.1. US East Coast Biotech Corridor

12.5.2. US West Coast Innovation Hub

12.5.3. UK Golden Triangle

12.5.4. Swiss Life Sciences Cluster

12.5.5. Nordic Drug Discovery Ecosystem

12.5.6. China Biopharma Innovation Centers

12.6. Buyer Scale Classification

12.6.1. Top 20 Global Pharma

12.6.2. Mid-Market Biotech

12.6.3. Early-Stage Venture-Funded Firms

12.6.4. Academic Research Organizations

12.7. Procurement Models

12.7.1. Direct Discovery Contracts

12.7.2. Multi-Year Research Agreements

12.7.3. Milestone-Based Collaborations

12.7.4. Strategic Platform Partnerships

12.8. Buying Triggers

12.8.1. Novel Target Discovery Requirements

12.8.2. Internal Pipeline Expansion

12.8.3. Accelerated Hit Identification

12.8.4. Difficult-to-Drug Targets

12.8.5. Portfolio Diversification

12.9. Decision-Maker Roles

12.9.1. Chief Scientific Officers

12.9.2. Heads of Drug Discovery

12.9.3. VP Translational Research

12.9.4. VP Biology

12.9.5. Discovery Program Leaders

12.9.6. External Innovation Teams

12.10. Budget Ownership

12.10.1. R&D Leadership

12.10.2. Therapeutic Area Heads

12.10.3. Platform Technology Teams

12.10.4. Business Development Groups

12.11. Vendor Selection Criteria

12.11.1. Library Diversity

12.11.2. Cellular Screening Capability

12.11.3. Hit Validation Success Rates

12.11.4. Scientific Expertise

12.11.5. Partnership Flexibility

12.11.6. Data Quality

12.12. Contract Value Bands

12.12.1. Pilot Projects

12.12.2. Program-Based Agreements

12.12.3. Multi-Target Discovery Partnerships

12.12.4. Enterprise Strategic Collaborations

12.13. Sales Cycle Length

12.13.1. Exploratory Evaluation

12.13.2. Scientific Assessment

12.13.3. Pilot Validation

12.13.4. Contract Negotiation

12.13.5. Multi-Year Engagement

12.14. Strategic Relevance for Vipergen

12.14.1. High-Value Discovery Collaborations

12.14.2. Expansion Among Top-Tier Pharma Accounts

12.14.3. Penetration into US Biotech Ecosystem

12.14.4. Growth in Translational Medicine Programs

13. By Region

13.1. Global

14. Global Market Analysis and Forecast (2026–2030)

14.1. Introduction

14.2. Market Share Analysis

14.3. Market Size and Forecast

14.4. Market Size and Forecast, By Geography

14.4.1. Europe

14.4.1.1. Market Share Analysis

14.4.1.2. Market Size and Forecast

14.4.1.3. By Product

14.4.1.4. By Technology

14.4.1.5. By Application

14.4.1.6. By Customer

14.4.1.7. Denmark

14.4.1.7.1. Market Share Analysis

14.4.1.7.2. Market Size and Forecast

14.4.1.7.3. By Product

14.4.1.7.4. By Technology

14.4.1.7.5. By Application

14.4.1.7.6. By Customer

14.4.1.8. United Kingdom

14.4.1.8.1. Market Share Analysis

14.4.1.8.2. Market Size and Forecast

14.4.1.8.3. By Product

14.4.1.8.4. By Technology

14.4.1.8.5. By Application

14.4.1.8.6. By Customer

14.4.1.9. Germany

14.4.1.9.1. Market Share Analysis

14.4.1.9.2. Market Size and Forecast

14.4.1.9.3. By Product

14.4.1.9.4. By Technology

14.4.1.9.5. By Application

14.4.1.9.6. By Customer

14.4.1.10. France

14.4.1.10.1. Market Share Analysis

14.4.1.10.2. Market Size and Forecast

14.4.1.10.3. By Product

14.4.1.10.4. By Technology

14.4.1.10.5. By Application

14.4.1.10.6. By Customer

14.4.1.11. Switzerland

14.4.1.11.1. Market Share Analysis

14.4.1.11.2. Market Size and Forecast

14.4.1.11.3. By Product

14.4.1.11.4. By Technology

14.4.1.11.5. By Application

14.4.1.11.6. By Customer

14.4.1.12. Netherlands

14.4.1.12.1. Market Share Analysis

14.4.1.12.2. Market Size and Forecast

14.4.1.12.3. By Product

14.4.1.12.4. By Technology

14.4.1.12.5. By Application

14.4.1.12.6. By Customer

14.4.1.13. Sweden

14.4.1.13.1. Market Share Analysis

14.4.1.13.2. Market Size and Forecast

14.4.1.13.3. By Product

14.4.1.13.4. By Technology

14.4.1.13.5. By Application

14.4.1.13.6. By Customer

14.4.1.14. Belgium

14.4.1.14.1. Market Share Analysis

14.4.1.14.2. Market Size and Forecast

14.4.1.14.3. By Product

14.4.1.14.4. By Technology

14.4.1.14.5. By Application

14.4.1.14.6. By Customer

14.4.2. North America

14.4.2.1. Market Share Analysis

14.4.2.2. Market Size and Forecast

14.4.2.3. By Product

14.4.2.4. By Technology

14.4.2.5. By Application

14.4.2.6. By Customer

14.4.2.7. United States

14.4.2.7.1. Market Share Analysis

14.4.2.7.2. Market Size and Forecast

14.4.2.7.3. By Product

14.4.2.7.4. By Technology

14.4.2.7.5. By Application

14.4.2.7.6. By Customer

14.4.2.8. Canada

14.4.2.8.1. Market Share Analysis

14.4.2.8.2. Market Size and Forecast

14.4.2.8.3. By Product

14.4.2.8.4. By Technology

14.4.2.8.5. By Application

14.4.2.8.6. By Customer

14.4.3. Asia-Pacific

14.4.3.1. Market Share Analysis

14.4.3.2. Market Size and Forecast

14.4.3.3. By Product

14.4.3.4. By Technology

14.4.3.5. By Application

14.4.3.6. By Customer

14.4.3.7. China

14.4.3.7.1. Market Share Analysis

14.4.3.7.2. Market Size and Forecast

14.4.3.7.3. By Product

14.4.3.7.4. By Technology

14.4.3.7.5. By Application

14.4.3.7.6. By Customer

14.4.3.8. Japan

14.4.3.8.1. Market Share Analysis

14.4.3.8.2. Market Size and Forecast

14.4.3.8.3. By Product

14.4.3.8.4. By Technology

14.4.3.8.5. By Application

14.4.3.8.6. By Customer

14.4.3.9. South Korea

14.4.3.9.1. Market Share Analysis

14.4.3.9.2. Market Size and Forecast

14.4.3.9.3. By Product

14.4.3.9.4. By Technology

14.4.3.9.5. By Application

14.4.3.9.6. By Customer

14.4.3.10. Singapore

14.4.3.10.1. Market Share Analysis

14.4.3.10.2. Market Size and Forecast

14.4.3.10.3. By Product

14.4.3.10.4. By Technology

14.4.3.10.5. By Application

14.4.3.10.6. By Customer

14.4.3.11. Australia

14.4.3.11.1. Market Share Analysis

14.4.3.11.2. Market Size and Forecast

14.4.3.11.3. By Product

14.4.3.11.4. By Technology

14.4.3.11.5. By Application

14.4.3.11.6. By Customer

14.5. Qualitative Market Insights

14.5.1. State and City Level Demand Clusters Named in the Source Cut Across All Three Regions Covered: Copenhagen in Denmark, Cambridge, Oxford and London in the United Kingdom, Basel and Zurich in Switzerland, Berlin and Munich in Germany, Paris in France, Boston, San Diego, the San Francisco Bay Area and New York in the United States, Toronto in Canada, Shanghai and Beijing in China, Tokyo and Osaka in Japan, Seoul in South Korea, and Singapore.

15. Competition Analysis

15.1. Market Positioning Overview

15.1.1. Global vs Regional Positioning

15.1.2. Proprietary DEL Platform Differentiation

15.1.3. Cellular Screening Capabilities Comparison

15.1.4. Service Versus Platform-Centric Business Models

15.1.5. Scientific Specialization Benchmarking

15.2. Competitive Benchmarking Metrics

15.2.1. Market Presence

15.2.2. Discovery Partnership Portfolio

15.2.3. Screening Technology Capabilities

15.2.4. Library Scale and Diversity

15.2.5. Scientific Workforce

15.2.6. Geographic Reach

15.2.7. Innovation Intensity

15.2.8. Strategic Alliance Activity

15.3. Strategic Moves

15.3.1. Drug Discovery Collaborations

15.3.2. Pharmaceutical Partnerships

15.3.3. Platform Expansions

15.3.4. Technology Licensing Agreements

15.3.5. Investment and Funding Activities

15.3.6. Research Alliances

15.4. Competitive Mapping & Gaps

15.4.1. Underserved Target Classes

15.4.2. Emerging Therapeutic Opportunities

15.4.3. Geographic Coverage Gaps

15.4.4. Service Differentiation Opportunities

15.4.5. AI-Enabled Discovery Integration Gaps

16. Company Profiles

16.1. Vipergen

16.1.1. Company Overview

16.1.2. Headquarters

16.1.3. Ownership Structure

16.1.4. Founding Year

16.1.5. Workforce Estimate

16.1.6. Geographic Footprint

16.1.7. Cellular DEL Capabilities

16.1.8. DEL Technology Portfolio

16.1.9. Target Customer Segments

16.1.10. Discovery Partnership Strategy

16.1.11. Distribution and GTM Model

16.1.12. Financial Highlights

16.1.13. Scientific Certifications

16.1.14. Strategic Partnerships

16.1.15. Research Collaborations

16.1.16. R&D Investments

16.1.17. Recent Developments

16.1.18. SWOT Snapshot

16.2. X-Chem

16.2.1. Company Overview

16.2.2. Headquarters

16.2.3. Ownership Structure

16.2.4. Founding Year

16.2.5. Workforce Estimate

16.2.6. Geographic Footprint

16.2.7. Cellular DEL Capabilities

16.2.8. DEL Technology Portfolio

16.2.9. Target Customer Segments

16.2.10. Discovery Partnership Strategy

16.2.11. Distribution and GTM Model

16.2.12. Financial Highlights

16.2.13. Scientific Certifications

16.2.14. Strategic Partnerships

16.2.15. Research Collaborations

16.2.16. R&D Investments

16.2.17. Recent Developments

16.2.18. SWOT Snapshot

16.3. HitGen

16.3.1. Company Overview

16.3.2. Headquarters

16.3.3. Ownership Structure

16.3.4. Founding Year

16.3.5. Workforce Estimate

16.3.6. Geographic Footprint

16.3.7. Cellular DEL Capabilities

16.3.8. DEL Technology Portfolio

16.3.9. Target Customer Segments

16.3.10. Discovery Partnership Strategy

16.3.11. Distribution and GTM Model

16.3.12. Financial Highlights

16.3.13. Scientific Certifications

16.3.14. Strategic Partnerships

16.3.15. Research Collaborations

16.3.16. R&D Investments

16.3.17. Recent Developments

16.3.18. SWOT Snapshot

16.4. WuXi AppTec

16.4.1. Company Overview

16.4.2. Headquarters

16.4.3. Ownership Structure

16.4.4. Founding Year

16.4.5. Workforce Estimate

16.4.6. Geographic Footprint

16.4.7. Cellular DEL Capabilities

16.4.8. DEL Technology Portfolio

16.4.9. Target Customer Segments

16.4.10. Discovery Partnership Strategy

16.4.11. Distribution and GTM Model

16.4.12. Financial Highlights

16.4.13. Scientific Certifications

16.4.14. Strategic Partnerships

16.4.15. Research Collaborations

16.4.16. R&D Investments

16.4.17. Recent Developments

16.4.18. SWOT Snapshot

16.5. Deluge Biotechnologies

16.5.1. Company Overview

16.5.2. Headquarters

16.5.3. Ownership Structure

16.5.4. Founding Year

16.5.5. Workforce Estimate

16.5.6. Geographic Footprint

16.5.7. Cellular DEL Capabilities

16.5.8. DEL Technology Portfolio

16.5.9. Target Customer Segments

16.5.10. Discovery Partnership Strategy

16.5.11. Distribution and GTM Model

16.5.12. Financial Highlights

16.5.13. Scientific Certifications

16.5.14. Strategic Partnerships

16.5.15. Research Collaborations

16.5.16. R&D Investments

16.5.17. Recent Developments

16.5.18. SWOT Snapshot

16.6. Nuevolution

16.6.1. Company Overview

16.6.2. Headquarters

16.6.3. Ownership Structure

16.6.4. Founding Year

16.6.5. Workforce Estimate

16.6.6. Geographic Footprint

16.6.7. Cellular DEL Capabilities

16.6.8. DEL Technology Portfolio

16.6.9. Target Customer Segments

16.6.10. Discovery Partnership Strategy

16.6.11. Distribution and GTM Model

16.6.12. Financial Highlights

16.6.13. Scientific Certifications

16.6.14. Strategic Partnerships

16.6.15. Research Collaborations

16.6.16. R&D Investments

16.6.17. Recent Developments

16.6.18. SWOT Snapshot

16.7. GSK DEL Technologies

16.7.1. Company Overview

16.7.2. Headquarters

16.7.3. Ownership Structure

16.7.4. Founding Year

16.7.5. Workforce Estimate

16.7.6. Geographic Footprint

16.7.7. Cellular DEL Capabilities

16.7.8. DEL Technology Portfolio

16.7.9. Target Customer Segments

16.7.10. Discovery Partnership Strategy

16.7.11. Distribution and GTM Model

16.7.12. Financial Highlights

16.7.13. Scientific Certifications

16.7.14. Strategic Partnerships

16.7.15. Research Collaborations

16.7.16. R&D Investments

16.7.17. Recent Developments

16.7.18. SWOT Snapshot

16.8. Pfizer Center for DNA-Encoded Chemistry

16.8.1. Company Overview

16.8.2. Headquarters

16.8.3. Ownership Structure

16.8.4. Founding Year

16.8.5. Workforce Estimate

16.8.6. Geographic Footprint

16.8.7. Cellular DEL Capabilities

16.8.8. DEL Technology Portfolio

16.8.9. Target Customer Segments

16.8.10. Discovery Partnership Strategy

16.8.11. Distribution and GTM Model

16.8.12. Financial Highlights

16.8.13. Scientific Certifications

16.8.14. Strategic Partnerships

16.8.15. Research Collaborations

16.8.16. R&D Investments

16.8.17. Recent Developments

16.8.18. SWOT Snapshot

16.9. Novartis DEL Platform

16.9.1. Company Overview

16.9.2. Headquarters

16.9.3. Ownership Structure

16.9.4. Founding Year

16.9.5. Workforce Estimate

16.9.6. Geographic Footprint

16.9.7. Cellular DEL Capabilities

16.9.8. DEL Technology Portfolio

16.9.9. Target Customer Segments

16.9.10. Discovery Partnership Strategy

16.9.11. Distribution and GTM Model

16.9.12. Financial Highlights

16.9.13. Scientific Certifications

16.9.14. Strategic Partnerships

16.9.15. Research Collaborations

16.9.16. R&D Investments

16.9.17. Recent Developments

16.9.18. SWOT Snapshot

16.10. AstraZeneca Discovery Sciences

16.10.1. Company Overview

16.10.2. Headquarters

16.10.3. Ownership Structure

16.10.4. Founding Year

16.10.5. Workforce Estimate

16.10.6. Geographic Footprint

16.10.7. Cellular DEL Capabilities

16.10.8. DEL Technology Portfolio

16.10.9. Target Customer Segments

16.10.10. Discovery Partnership Strategy

16.10.11. Distribution and GTM Model

16.10.12. Financial Highlights

16.10.13. Scientific Certifications

16.10.14. Strategic Partnerships

16.10.15. Research Collaborations

16.10.16. R&D Investments

16.10.17. Recent Developments

16.10.18. SWOT Snapshot

16.11. Bristol Myers Squibb Discovery Platforms

16.11.1. Company Overview

16.11.2. Headquarters

16.11.3. Ownership Structure

16.11.4. Founding Year

16.11.5. Workforce Estimate

16.11.6. Geographic Footprint

16.11.7. Cellular DEL Capabilities

16.11.8. DEL Technology Portfolio

16.11.9. Target Customer Segments

16.11.10. Discovery Partnership Strategy

16.11.11. Distribution and GTM Model

16.11.12. Financial Highlights

16.11.13. Scientific Certifications

16.11.14. Strategic Partnerships

16.11.15. Research Collaborations

16.11.16. R&D Investments

16.11.17. Recent Developments

16.11.18. SWOT Snapshot

16.12. Roche Pharma Research & Early Development

16.12.1. Company Overview

16.12.2. Headquarters

16.12.3. Ownership Structure

16.12.4. Founding Year

16.12.5. Workforce Estimate

16.12.6. Geographic Footprint

16.12.7. Cellular DEL Capabilities

16.12.8. DEL Technology Portfolio

16.12.9. Target Customer Segments

16.12.10. Discovery Partnership Strategy

16.12.11. Distribution and GTM Model

16.12.12. Financial Highlights

16.12.13. Scientific Certifications

16.12.14. Strategic Partnerships

16.12.15. Research Collaborations

16.12.16. R&D Investments

16.12.17. Recent Developments

16.12.18. SWOT Snapshot

16.13. AbbVie Discovery Research

16.13.1. Company Overview

16.13.2. Headquarters

16.13.3. Ownership Structure

16.13.4. Founding Year

16.13.5. Workforce Estimate

16.13.6. Geographic Footprint

16.13.7. Cellular DEL Capabilities

16.13.8. DEL Technology Portfolio

16.13.9. Target Customer Segments

16.13.10. Discovery Partnership Strategy

16.13.11. Distribution and GTM Model

16.13.12. Financial Highlights

16.13.13. Scientific Certifications

16.13.14. Strategic Partnerships

16.13.15. Research Collaborations

16.13.16. R&D Investments

16.13.17. Recent Developments

16.13.18. SWOT Snapshot

16.14. Genentech

16.14.1. Company Overview

16.14.2. Headquarters

16.14.3. Ownership Structure

16.14.4. Founding Year

16.14.5. Workforce Estimate

16.14.6. Geographic Footprint

16.14.7. Cellular DEL Capabilities

16.14.8. DEL Technology Portfolio

16.14.9. Target Customer Segments

16.14.10. Discovery Partnership Strategy

16.14.11. Distribution and GTM Model

16.14.12. Financial Highlights

16.14.13. Scientific Certifications

16.14.14. Strategic Partnerships

16.14.15. Research Collaborations

16.14.16. R&D Investments

16.14.17. Recent Developments

16.14.18. SWOT Snapshot

16.15. Exscientia Discovery Partnerships

16.15.1. Company Overview

16.15.2. Headquarters

16.15.3. Ownership Structure

16.15.4. Founding Year

16.15.5. Workforce Estimate

16.15.6. Geographic Footprint

16.15.7. Cellular DEL Capabilities

16.15.8. DEL Technology Portfolio

16.15.9. Target Customer Segments

16.15.10. Discovery Partnership Strategy

16.15.11. Distribution and GTM Model

16.15.12. Financial Highlights

16.15.13. Scientific Certifications

16.15.14. Strategic Partnerships

16.15.15. Research Collaborations

16.15.16. R&D Investments

16.15.17. Recent Developments

16.15.18. SWOT Snapshot

16.16. Proteros biostructures

16.16.1. Company Overview

16.16.2. Headquarters

16.16.3. Ownership Structure

16.16.4. Founding Year

16.16.5. Workforce Estimate

16.16.6. Geographic Footprint

16.16.7. Cellular DEL Capabilities

16.16.8. DEL Technology Portfolio

16.16.9. Target Customer Segments

16.16.10. Discovery Partnership Strategy

16.16.11. Distribution and GTM Model

16.16.12. Financial Highlights

16.16.13. Scientific Certifications

16.16.14. Strategic Partnerships

16.16.15. Research Collaborations

16.16.16. R&D Investments

16.16.17. Recent Developments

16.16.18. SWOT Snapshot

16.17. Evotec

16.17.1. Company Overview

16.17.2. Headquarters

16.17.3. Ownership Structure

16.17.4. Founding Year

16.17.5. Workforce Estimate

16.17.6. Geographic Footprint

16.17.7. Cellular DEL Capabilities

16.17.8. DEL Technology Portfolio

16.17.9. Target Customer Segments

16.17.10. Discovery Partnership Strategy

16.17.11. Distribution and GTM Model

16.17.12. Financial Highlights

16.17.13. Scientific Certifications

16.17.14. Strategic Partnerships

16.17.15. Research Collaborations

16.17.16. R&D Investments

16.17.17. Recent Developments

16.17.18. SWOT Snapshot

16.18. Charles River Laboratories

16.18.1. Company Overview

16.18.2. Headquarters

16.18.3. Ownership Structure

16.18.4. Founding Year

16.18.5. Workforce Estimate

16.18.6. Geographic Footprint

16.18.7. Cellular DEL Capabilities

16.18.8. DEL Technology Portfolio

16.18.9. Target Customer Segments

16.18.10. Discovery Partnership Strategy

16.18.11. Distribution and GTM Model

16.18.12. Financial Highlights

16.18.13. Scientific Certifications

16.18.14. Strategic Partnerships

16.18.15. Research Collaborations

16.18.16. R&D Investments

16.18.17. Recent Developments

16.18.18. SWOT Snapshot

Frequently Asked Questions

The global cellular DEL screening market is estimated at approximately USD 1.6 Billion in 2025 and is forecast to reach approximately USD 2.9 Billion by 2030, growing at a compound annual growth rate of approximately 12.6 percent, derived by triangulating a published total DNA-encoded library market estimate against this report's own segmentation boundary.

This report covers six screening technology categories: cellular DEL screening, live cell-based DEL screening, phenotypic DEL screening, target-based DEL screening, affinity selection DEL screening and covalent DEL screening, alongside five DEL chemistry platform categories that determine which library types each technology can be run against.

North America holds the largest regional concentration, anchored by the US East Coast and West Coast biotech corridors, while Asia-Pacific is the fastest-growing region, led by China's expanding biopharma innovation centers alongside growth in Japan, South Korea, Singapore and Australia.

Oncology is the largest therapeutic application category by discovery partnership volume, with immunology and inflammation programs growing at a faster relative pace as difficult-to-drug immune-pathway targets draw increased investment; neuroscience, infectious diseases, metabolic disorders, rare diseases and cardiovascular diseases round out this report's seven tracked therapeutic application categories.

End users include large pharmaceutical companies, emerging biotech companies, contract research organizations, academic research institutes, translational medicine centers and government research organizations, each typically accessing DEL screening through a different engagement model suited to its own discovery budget and program structure.

Buyers can access DEL screening through fee-for-service screening, discovery partnership programs, co-development agreements, licensing arrangements or platform access models, with the choice generally shaped by how much internal control over library design and screening cadence a program requires.

Companies covered include Vipergen, X-Chem, HitGen, WuXi AppTec, Deluge Biotechnologies, Nuevolution, GSK DEL Technologies, Pfizer Center for DNA-Encoded Chemistry, Novartis DEL Platform, AstraZeneca Discovery Sciences, Bristol Myers Squibb Discovery Platforms, Roche Pharma Research & Early Development, AbbVie Discovery Research, Genentech, Exscientia Discovery Partnerships, Proteros biostructures, Evotec and Charles River Laboratories.

This report tracks seven target class categories: GPCRs, kinases, protein-protein interactions, transcription factors, ion channels, E3 ligases and novel intracellular targets, several of which are difficult-to-drug categories that conventional biochemical screening approaches have historically struggled to address.

No. Conventional high-throughput biochemical screening tests compounds individually against a target, while DEL screening attaches a unique DNA barcode to each molecule in a very large synthesized library so that surviving hits can be identified by sequencing rather than one-by-one testing, which is why this report treats DEL screening as a distinct technology category.

Inquire Before Buying Request Free Sample Ask For Discount

Primary data anchor: the total DNA-encoded library (DEL) market as the closest published category

Cellular DEL screening is frequently reported inside a broader total DNA-encoded library (DEL) market category, which spans every DEL screening approach together rather than isolating any one screening technology on its own. A published industry estimate places the total global DNA-encoded library market at approximately USD 1.8 Billion in 2026, rising to approximately USD 5.9 Billion by 2036 at a compound annual growth rate of approximately 12.7 percent, with named participants in that estimate including X-Chem, HitGen, WuXi AppTec, Vipergen and Charles River Laboratories, the same core provider set covered in this report's own Companies Covered list. This report's own segmentation, spanning cellular, live cell-based, phenotypic, target-based, affinity selection and covalent DEL screening together, aligns closely with that total category rather than a narrower slice of it, so the total DNA-encoded library market is used as this report's primary data anchor rather than an adjacent but different technology category.

Derivation to this report's 2025 base year

The published estimate above uses a 2026 base year rather than the 2025 base year convention used throughout this report. Applying the same published compound annual growth rate of approximately 12.7 percent in reverse, a 2026 figure of approximately USD 1.8 Billion implies a 2025 figure of approximately USD 1.6 Billion. This 2025 baseline is the figure carried into the market snapshot table above, keeping this report's base year consistent with its own forecast period convention while remaining directly traceable to the published 2026 anchor figure.

Cross-check against screening-method composition

The same published estimate breaks the total DNA-encoded library market down by screening method, with affinity-based screening representing approximately 48 percent of 2026 market value, the largest single method category, and the remaining share split across cellular, phenotypic and other screening approaches. This report's own screening technology segmentation includes affinity selection DEL screening as one of six named categories alongside cellular DEL screening, which is consistent with affinity-based approaches holding the largest individual share while cellular and other approaches continue to represent a substantial and growing remainder. This cross-check supports using the total category figure without a downward adjustment, since this report's scope was defined from the outset to span the full screening-method mix rather than isolating affinity-based screening alone.

Forecast basis and its principal sensitivity

Applying the same approximately 12.7 percent compound annual growth rate forward from the 2025 baseline of approximately USD 1.6 Billion produces a 2030 forecast of approximately USD 2.9 Billion, consistent with the country-level growth rates in the published estimate, which range from approximately 12.4 percent in Germany to approximately 13.7 percent in South Korea across the 2026 to 2036 window. The principal sensitivity behind this forecast is the pace at which discovery partnership programs and platform access models convert from pilot validation into full multi-year agreements, since buyer R&D budget cycles and the scientific assessment period preceding any new partnership commitment are the two factors most likely to slow or accelerate this market's realized growth relative to the published trajectory.

Frequently Asked Questions

The global cellular DEL screening market is estimated at approximately USD 1.6 Billion in 2025 and is forecast to reach approximately USD 2.9 Billion by 2030, growing at a compound annual growth rate of approximately 12.6 percent, derived by triangulating a published total DNA-encoded library market estimate against this report's own segmentation boundary.

This report covers six screening technology categories: cellular DEL screening, live cell-based DEL screening, phenotypic DEL screening, target-based DEL screening, affinity selection DEL screening and covalent DEL screening, alongside five DEL chemistry platform categories that determine which library types each technology can be run against.

North America holds the largest regional concentration, anchored by the US East Coast and West Coast biotech corridors, while Asia-Pacific is the fastest-growing region, led by China's expanding biopharma innovation centers alongside growth in Japan, South Korea, Singapore and Australia.

Oncology is the largest therapeutic application category by discovery partnership volume, with immunology and inflammation programs growing at a faster relative pace as difficult-to-drug immune-pathway targets draw increased investment; neuroscience, infectious diseases, metabolic disorders, rare diseases and cardiovascular diseases round out this report's seven tracked therapeutic application categories.

End users include large pharmaceutical companies, emerging biotech companies, contract research organizations, academic research institutes, translational medicine centers and government research organizations, each typically accessing DEL screening through a different engagement model suited to its own discovery budget and program structure.

Buyers can access DEL screening through fee-for-service screening, discovery partnership programs, co-development agreements, licensing arrangements or platform access models, with the choice generally shaped by how much internal control over library design and screening cadence a program requires.

Companies covered include Vipergen, X-Chem, HitGen, WuXi AppTec, Deluge Biotechnologies, Nuevolution, GSK DEL Technologies, Pfizer Center for DNA-Encoded Chemistry, Novartis DEL Platform, AstraZeneca Discovery Sciences, Bristol Myers Squibb Discovery Platforms, Roche Pharma Research & Early Development, AbbVie Discovery Research, Genentech, Exscientia Discovery Partnerships, Proteros biostructures, Evotec and Charles River Laboratories.

This report tracks seven target class categories: GPCRs, kinases, protein-protein interactions, transcription factors, ion channels, E3 ligases and novel intracellular targets, several of which are difficult-to-drug categories that conventional biochemical screening approaches have historically struggled to address.

No. Conventional high-throughput biochemical screening tests compounds individually against a target, while DEL screening attaches a unique DNA barcode to each molecule in a very large synthesized library so that surviving hits can be identified by sequencing rather than one-by-one testing, which is why this report treats DEL screening as a distinct technology category.

Inquire Before Buying Request Free Sample Ask For Discount